The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10517 malaria professionals are enjoying the free benefits of MalariaWorld today

randomized trial

Estimation of the primary, secondary and composite effects of malaria vaccines using data on multiple clinical malaria episodes

June 17, 2020 - 12:49 -- Open Access
Author(s): 
Cheung YB, Ma X, Lam KF, Milligan P
Reference: 
Vaccine. 2020 Jun 11:S0264-410X(20)30753-2

An effective malaria vaccine affects the risk of malaria directly, through the vaccine-induced immune response (the primary effect), and indirectly, as a consequence of reduced exposure to malaria infection and disease, leading to slower acquisition of natural immunity (the secondary effect). The beneficial primary effect may be offset by a negative secondary effect, resulting in a smaller or nil composite effect. Reports of malaria vaccine trials usually present only the composite effect. We aimed to demonstrate how the primary and secondary effects can also be estimated from trial data.

Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01E malaria vaccine in African children: a randomized trial

January 24, 2020 - 15:04 -- Open Access
Author(s): 
Valéa I, Adjei S, Agbenyega T, et al.
Reference: 
Hum Vaccin Immunother. 2020 Jan 17:1-7

RTS,S/AS01E malaria vaccine contains the hepatitis B virus surface antigen and may thus serve as a potential hepatitis B vaccine. To evaluate the impact of RTS,S/AS01E when implemented in the Expanded Program of Immunization, infants 8–12 weeks old were randomized to receive either RTS,S/AS01E or a licensed hepatitis B control vaccine (HepB), both co-administered with various combinations of the following childhood vaccines: diphtheria-tetanus-acellular pertussis-Haemophilus influenzae type b, trivalent oral poliovirus, pneumococcal non-typeable Haemophilus influenzae protein D conjugate and human rotavirus vaccine.

Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa

January 24, 2020 - 14:40 -- Open Access
Author(s): 
Otieno L, Guerra Mendoza Y, Oneko M, et al.
Reference: 
Vaccine Volume 38, Issue 4, 22 January 2020, Pages 897-906

We assessed the safety and immunogenicity of the RTS,S/AS01 malaria vaccine in a subset of children identified as HIV-infected during a large phase III randomized controlled trial conducted in seven sub-Saharan African countries.

Subscribe to RSS - randomized trial